HDL as a biomarker, potential therapeutic target, and therapy.
Navab
Mohamad
M
Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA. mnavab@mednet.ucla.edu
Anantharamaiah
G M
GM
Reddy
Srinivasa T
ST
Van Lenten
Brian J
BJ
Fogelman
Alan M
AM
D000210:Acute-Phase Reaction / Q000378:metabolism*; D000818:Animals; D017849:Animals, Inbred Strains; D016632:Apolipoprotein A-I / Q000378:metabolism; D015415:Biomarkers; D008076:Cholesterol, HDL / Q000097:blood / Q000378:metabolism*; D008078:Cholesterol, LDL / Q000378:metabolism; D003327:Coronary Disease / Q000378:metabolism; D003920:Diabetes Mellitus / Q000378:metabolism*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000378:metabolism; D007918:Leprosy / Q000378:metabolism; D015227:Lipid Peroxidation; D008180:Lupus Erythematosus, Systemic / Q000378:metabolism; D024821:Metabolic Syndrome / Q000378:metabolism; D051379:Mice; D009765:Obesity / Q000378:metabolism; D018384:Oxidative Stress; D011237:Predictive Value of Tests; D011817:Rabbits; D018570:Risk Assessment; D012307:Risk Factors
D016632:Apolipoprotein A-I; D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006454:Hemoglobins